Boston Scientific Co. (NYSE:BSX) Stock Holdings Cut by Lighthouse Investment Partners LLC

Lighthouse Investment Partners LLC decreased its stake in Boston Scientific Co. (NYSE:BSX - Free Report) by 86.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 20,000 shares of the medical equipment provider's stock after selling 122,762 shares during the period. Lighthouse Investment Partners LLC's holdings in Boston Scientific were worth $1,786,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. TFC Financial Management Inc. grew its position in Boston Scientific by 308.8% in the fourth quarter. TFC Financial Management Inc. now owns 278 shares of the medical equipment provider's stock valued at $25,000 after acquiring an additional 210 shares in the last quarter. Colonial Trust Co SC boosted its stake in shares of Boston Scientific by 1,625.0% in the fourth quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider's stock valued at $25,000 after purchasing an additional 260 shares during the period. West Oak Capital LLC acquired a new stake in Boston Scientific during the 4th quarter valued at $29,000. Valley National Advisers Inc. increased its stake in Boston Scientific by 262.4% during the 4th quarter. Valley National Advisers Inc. now owns 395 shares of the medical equipment provider's stock worth $35,000 after buying an additional 286 shares during the period. Finally, Fairway Wealth LLC acquired a new position in Boston Scientific in the 4th quarter worth $36,000. Institutional investors and hedge funds own 89.07% of the company's stock.

Analyst Ratings Changes

Several analysts have recently weighed in on BSX shares. Needham & Company LLC raised their target price on Boston Scientific from $113.00 to $115.00 and gave the company a "buy" rating in a research note on Thursday, April 24th. Evercore ISI raised their price objective on Boston Scientific from $110.00 to $112.00 and gave the company an "outperform" rating in a research note on Thursday, April 24th. Barclays lifted their price objective on Boston Scientific from $118.00 to $125.00 and gave the stock an "overweight" rating in a report on Friday, April 25th. Stifel Nicolaus increased their target price on Boston Scientific from $100.00 to $115.00 and gave the company a "buy" rating in a research note on Thursday, February 6th. Finally, Citigroup lifted their price target on shares of Boston Scientific from $107.00 to $122.00 and gave the stock a "buy" rating in a research note on Thursday, February 6th. Twenty-three research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $114.74.

Insider Activity at Boston Scientific

In related news, CEO Michael F. Mahoney sold 164,443 shares of Boston Scientific stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $102.48, for a total transaction of $16,852,118.64. Following the sale, the chief executive officer now directly owns 1,535,706 shares in the company, valued at $157,379,150.88. The trade was a 9.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP John Bradley Sorenson sold 2,657 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $104.41, for a total transaction of $277,417.37. Following the completion of the transaction, the executive vice president now owns 24,294 shares of the company's stock, valued at $2,536,536.54. This represents a 9.86% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 265,820 shares of company stock worth $27,406,958 in the last ninety days. 0.50% of the stock is owned by insiders.

Boston Scientific Stock Performance

Shares of Boston Scientific stock traded up $0.41 on Monday, reaching $106.45. 1,536,392 shares of the company were exchanged, compared to its average volume of 6,344,194. The firm has a market cap of $157.49 billion, a price-to-earnings ratio of 85.11, a P/E/G ratio of 2.79 and a beta of 0.68. Boston Scientific Co. has a 1-year low of $71.88 and a 1-year high of $107.17. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.02 and a current ratio of 1.08. The company's 50-day moving average is $99.18 and its two-hundred day moving average is $96.74.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.08. The firm had revenue of $4.66 billion for the quarter, compared to analyst estimates of $4.57 billion. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. The firm's revenue for the quarter was up 20.9% on a year-over-year basis. During the same period last year, the company earned $0.56 earnings per share. As a group, research analysts expect that Boston Scientific Co. will post 2.85 earnings per share for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.